丙型肝炎病毒治愈对加拿大HIV-HCV合并感染人群抑郁症状的影响
在加拿大HIV-HCV合并感染人群中,采用中断时间序列设计分析470名获得持续病毒学应答(SVR)的参与者,发现SVR后抑郁症状患病率每年下降5%(风险比0.95,95%CI 0.94-0.96),而SVR前趋势变化很小且SVR时无即刻水平变化。
要点
- 纳入470名HIV-HCV合并感染者,58%在基线时存在预测的抑郁症状。
- SVR后抑郁症状患病率每年下降5%(风险比0.95,95%CI 0.94-0.96)。
- SVR前抑郁症状随时间变化很小,SVR时无即刻水平变化。
核心结论
- 在直接抗病毒药物时代,获得持续病毒学应答后预测的抑郁症状随时间下降。
- 这些改善可能反映生物学通路变化和/或总体健康状况改善。
- 如果抑郁症状的改善是持久的,这为治疗和早期治愈HCV提供了额外理由。
研究设计与样本
- 研究使用加拿大合并感染队列(CCC)数据,该队列为HIV和HCV合并感染者的多中心前瞻性队列。
- 抑郁筛查仅在其食物保障子研究中实施,故使用随机森林分类器预测CCC中流行病学研究中心抑郁量表-10的类别并校正误分类。
- 纳入470名达到持续病毒学应答的参与者,采用中断时间序列设计拟合分段修正泊松模型,并调整时变混杂因素。
主要发现
- 共纳入470名参与者,58%在基线时有预测的抑郁症状。
- SVR前中位随访时间为2.4年(四分位距[IQR]:1.0-4.5),SVR后中位随访时间为1.4年(IQR:0.6-2.5)。
- SVR前趋势提示抑郁症状随时间变化很小,SVR时无即刻水平变化。
- SVR后趋势显示抑郁症状患病率每年下降5%(风险比:0.95,95%置信区间[CI]:0.94-0.96)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression is common in people with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), with biological and psychosocial mechanisms at play. Direct acting antivirals (DAA) result in high rates of sustained virologic response (SVR), with minimal side-effects. We assessed the impact of SVR on presence of depressive symptoms in the HIV-HCV coinfected population in Canada during the second-generation DAA era (2013-2020). METHODS: We used data from the Canadian CoInfection Cohort (CCC), a multicenter prospective cohort of people with a HIV and HCV coinfection, and its associated sub-study on food security. Because depression screening was performed only in the sub-study, we predicted Center for Epidemiologic Studies Depression Scale-10 classes in the CCC using a random forest classifier and corrected for misclassification. We included participants who achieved SVR and fit a segmented modified Poisson model using an interrupted time series design, adjusting for time-varying confounders. RESULTS: We included 470 participants; 58% had predicted depressive symptoms at baseline. The median follow-up was 2.4 years (interquartile range [IQR]: 1.0-4.5.) pre-SVR and 1.4 years (IQR: 0.6-2.5) post-SVR. The pre-SVR trend suggested depressive symptoms changed little over time, with no immediate level change at SVR. However, post-SVR trends showed a reduction of 5% per year (risk ratio: 0.95 (95% confidence interval [CI]: .94-.96)) in the prevalence of depressive symptoms. CONCLUSIONS: In the DAA era, predicted depressive symptoms declined over time following SVR. These improvements reflect possible changes in biological pathways and/or better general health. If such improvements in depression symptoms are durable, this provides an additional reason for treatment and early cure of HCV.
引用
- Marathe G, Moodie EEM, Brouillette MJ, et al. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada. Clin Infect Dis. 2023. PMID: 35789253. doi:10.1093/cid/ciac540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。